This will also facilitate the manufacture of equivalent or comparable IND vaccines for future clinical trials. Adherence to cGMP during manufacture of Phase I investigational drugs is achieved mostly through well-defined written procedures, adequately controlled and calibrated

(certified) CP-868596 in vivo equipment and manufacturing environment, and accurately and consistently recorded data from manufacturing testing. Pharmacological and toxicological effects of new vaccines must be assessed before initiation of human studies and continued throughout clinical development. Both in vitro and in vivo data are used to assess preclinical safety. The goals of preclinical safety evaluation include evaluation of single-dose toxicity; repeated-dose toxicity; primary pharmacodynamics (immunogenicity); secondary pharmacodynamics (safety); pharmacokinetics and local tolerance. For the in vivo phase of preclinical testing, selection of the relevant animal species, age of test animals, their

physiological state, vaccine delivery (including dose, route of administration and treatment regimen) and stability of the test material under the conditions of use are necessary information to submit to regulatory authorities before clinical studies begin. Clinical development involves studies of the effects of vaccines on healthy volunteers for safety, immunogenicity and efficacy through a staged process. As shown in Figure 5.1, there are three distinct phases selleck products in the clinical development programme following preclinical acceptance of a vaccine candidate. Phase

I clinical studies are mainly safety studies, with some of them looking at dose-ranging as well. Phase II trials include immunogenicity proof-of-concept (and in some cases, efficacy) and dose-ranging, and carry the vaccine forward in increasing numbers of volunteers. Larger Phase III clinical trials are then conducted to determine the ability of a new vaccine to produce a desired clinical effect C-X-C chemokine receptor type 7 (CXCR-7) at an optimum dose and schedule with an acceptable safety profile. These are conducted and completed alongside consistency lot studies (for consistency of vaccine physicochemical and biological quality and effect among different vaccine lots). In addition, post-licensure trials, also known as Phase IV trials, include studies on new indications of use and safety surveillance studies (pharmacovigilance). Phase IV surveillance studies, because of the large sample size involved, are designed to detect very rare adverse events (AEs) that are difficult to pick up in Phase III studies.